샘플 요청 목록

 카트 문의
시장보고서
상품코드
1793844

세계의 경직 치료 시장

Spasticity Treatment
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 334 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 경직 치료 시장은 2030년까지 72억 달러에 도달

2024년에 59억 달러로 추정되는 세계의 경직 치료 시장은 분석 기간인 2024-2030년에 CAGR 3.2%로 성장하며, 2030년에는 72억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 경직 약물 요법은 CAGR 4.0%를 기록하며, 분석 기간 종료시에는 46억 달러에 달할 것으로 예측됩니다. 경직 물리치료 분야의 성장률은 분석 기간 중 CAGR 1.9%로 추정됩니다.

미국 시장은 16억 달러로 추정, 중국은 CAGR 6.2%로 성장 예측

미국의 경직 치료 시장은 2024년에 16억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 14억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 6.2%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 1.2%와 2.5%로 예측됩니다. 유럽에서는 독일이 CAGR 1.8%로 성장할 것으로 예측됩니다.

세계의 경직 치료 시장 - 주요 동향과 촉진요인 정리

근긴장 장애 관리: 새로운 치료법이 경련 치료와 환자 결과를 재정의하는 방법

경련이란 무엇이며, 왜 신경학적 치료 영역으로 점점 더 우선순위가 높아지는가?

경련은 비자발적인 근육의 경직, 과장된 반사, 수동적인 움직임에 대한 저항을 특징으로 하는 신경근 질환으로 중추신경계 손상으로 인해 발생하는 경우가 많습니다. 일반적인 기초 원인으로는 다발성 경화증(MS), 뇌성마비(CP), 외상성 뇌손상(TBI), 뇌졸중, 척수손상 등이 있습니다. 경련은 이동성과 정교함을 저해할 뿐만 아니라 관절구축, 통증, 장기적인 장애를 유발하여 환자의 QOL과 간병인의 부담에 큰 영향을 미칩니다.

세계에서 진단 능력과 급성기 이후 치료 시스템이 개선됨에 따라 경련과 관련된 합병증에 대한 인식과 발견이 증가하고 있습니다. 이 질환은 단순한 증상이 아닌 삶의 질에 광범위하게 영향을 미치는 교정 가능한 치료 대상으로 여겨지고 있습니다. 현재 임상 관리에는 약리학적, 재활적, 외과적, 신경조절적 접근법에 걸친 다학제적 개입이 포함됩니다. 환자 중심의 기능 회복 솔루션에 대한 수요가 증가함에 따라 경련 치료의 적용 범위는 소아에서 성인까지 확대되고 있습니다.

주요 치료 접근 방식과 환자 관리를 변화시키는 혁신은 무엇인가?

약물 치료는 여전히 치료의 첫 번째 선택이며, 바클로펜, 티자니딘, 디아제팜, 단토로렌 등의 경구용 진경제가 일반적으로 처방되고 있습니다. 그러나 이들 약물은 진정, 저혈압, 간독성 등 전신성 부작용을 유발하는 경우가 많아 장기간 사용에는 한계가 있습니다. 그 결과, 보툴리눔 톡신 A형(BoNT-A) 주사와 같은 국소 요법이 선호되고 있습니다. 이들 신경근 차단제는 신경근 접합부에서 아세틸콜린 방출을 선택적으로 억제하므로 전신에 미치는 영향이 적고, 표적화된 완화가 가능합니다. Botox(Allergan), Dysport(Ipsen), Xeomin(Merz) 등의 브랜드가 이 부문을 독점하고 있으며, 상지경련과 하지경련에 걸친 광범위한 임상시험 데이터가 지원하고 있습니다.

척수강내 바클로펜 요법(ITB)은 중증 전신 경련에 대한 또 다른 진보된 치료법입니다. 이는 프로그램 가능한 펌프를 내장하여 바클로펜을 척수에 직접 투여하여 전신에 대한 노출을 줄이고 효능을 향상시킵니다. ITB는 뇌성마비, 척수손상, 중증 뇌졸중 후 경련 환자에게 특히 효과적입니다. 힘줄 박리술, 선택적 배측 지골 절골술과 같은 외과적 수술은 난치성 환자나 변형 교정이 필요한 경우에 시행합니다. 물리치료와 작업치료는 근육 스트레칭, 부목, 기능 재교육에 중점을 두고 여전히 필수적인 보조 요법입니다.

새로운 기술 혁신으로는 경두개 자기자극(TMS), 전기자극요법 등 신경조절기술이 있는데, 이는 척수반사회로를 조절하고 자발적 운동 조절을 개선하는 것을 목표로 합니다. 디지털 치료법, AI를 활용한 보행 분석, 착용형 근전도(EMG) 센서도 경련 관리 경로에 통합되어 객관적인 모니터링과 맞춤형 치료 조정을 제공합니다. 줄기세포 연구와 재생치료는 특히 척수손상이나 뇌손상 환자에서 신경가소성 강화를 위한 초기 탐색 단계에 있습니다.

경련 치료의 성장을 주도하는 지역과 제공 모델의 진화는?

북미가 세계 경련 치료 시장을 선도하고 있는 것은 질환에 대한 높은 인식, 첨단 치료제에 대한 폭넓은 접근성, 신경과 및 재활센터의 강력한 생태계에 기인합니다. 미국은 BoNT-A 치료의 주요 시장이며, 보험 적용 범위가 넓고 환자 지원 단체가 조기 진단 및 개입을 지원하고 있습니다. 메디케이드, 재향군인회 등 정부 지원 프로그램도 외과적 치료와 기기 기반 치료에 대한 지원을 확대하여 의료 서비스를 충분히 받지 못하는 사람들에게 접근성을 높이고 있습니다.

유럽도 이에 이어 독일, 프랑스, 영국, 북유럽 국가 등에서 보툴리눔 톡신 요법을 널리 채택하고 있습니다. 국가 의료 서비스에서는 약물 치료와 수술적 치료에 대한 상환이 이루어지고 있으며, 연구 기관에서는 약물 치료와 로봇 치료의 병용과 같은 새로운 기술에 대한 평가가 활발히 이루어지고 있습니다. 이 지역의 재활 네트워크와 뇌졸중 병동은 경련의 통합적 관리를 중요시하며, 재활의학과, 신경과, 정형외과, 치료사를 포함한 다학제적 팀을 사용하는 경우가 많습니다.

아시아태평양은 중국, 일본, 인도, 한국 등의 국가에서 뇌졸중 및 외상 발생률 증가, 재활치료에 대한 접근성 향상, 의료 투자 증가로 인해 새로운 핫스팟으로 떠오르고 있습니다. BoNT-A 요법이나 ITB 요법에 대한 인지도나 전문의 유무에 따라 편차가 있지만, 도시 지역에서는 수요가 급증하고 있습니다. 라틴아메리카와 중동은 의료관광, 원격의료 상담, 장애인 케어에 초점을 맞춘 민관협력에 힘입어 경련 서비스를 점차 확대하고 있습니다.

시장 성장을 가속하는 요인은 무엇이며, 미래의 치료 프론티어는 어디에서 출현할 것으로 예상하는가?

세계 경련 치료 시장의 성장은 신경혈관질환 및 신경퇴행성 질환의 유병률 증가, 부상 후 생존율 향상, 저침습적이고 맞춤 치료 옵션의 등장 등 여러 요인에 의해 이루어지고 있습니다. 의료 시스템이 장기적인 기능적 결과와 장애 감소를 우선시함에 따라 경련 관리는 더 광범위한 신경 재활의 틀에 통합되고 있습니다. 주사 가능한 생물제제 및 프로그램 가능한 약물전달 시스템의 채택이 증가하고 있는 것은 표적화되고 지속가능한 치료 패러다임으로의 전환을 반영하고 있습니다.

파이프라인에는 효과 지속시간이 길고, 안전성 프로파일이 개선되고, 발현이 빠른 차세대 보툴리눔 톡신 제제가 포함되어 있습니다. 각 업체들은 바이오시밀러 개발을 진행하고 있으며, 소아 및 외상 후 환자를 대상으로 적응증 확대를 꾀하고 있습니다. BoNT-A와 로봇공학, 기능적 전기자극 등의 병용요법은 운동기능을 개선하고 간병인의 의존도를 감소시켜 유망 치료법으로 평가받고 있습니다. 또한 사용자 데이터에 따라 치료 강도를 조절하는 AI 기반 재활 플랫폼이 의료 프로바이더와 지불자 사이에서 관심을 받고 있습니다.

치료 성공의 정의가 근긴장 완화뿐만 아니라 삶의 질 지표, 기능적 독립성, 환자가 보고하는 결과 등으로 진화함에 따라 경련 치료 시장은 종합적인 기술 대응 영역으로 확대될 것입니다. 통합 치료 모델, 신경 기술, 디지털 바이오마커 추적에 대한 전략적 투자는 전 세계 경련 치료의 미래를 형성하는 데 매우 중요한 역할을 할 것으로 보입니다.

부문

유형(경직 약물 요법, 경직 물리치료, 경직 외과 치료), 투여 경로(경구투여, 비경구투여), 적응증(뇌성마비 적응증, 다발성 경화증 적응증, 외상성 뇌손상 적응증, 기타 적응증), 최종사용자(병원 최종사용자, 외래 수술 센터 최종사용자, 홈케어 시설 최종사용자, 전문 클리닉 최종사용자, 진단 센터 최종사용자)

조사 대상 기업의 예

  • AbbVie Inc.(Allergan)
  • Acorda Therapeutics, Inc.
  • Amneal Pharmaceuticals, Inc.
  • Assertio Therapeutics, Inc.
  • Beximco Pharmaceuticals Ltd.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc(GSK)
  • InMed Pharmaceuticals Inc.
  • Ipsen Biopharmaceuticals, Inc.
  • Jazz Pharmaceuticals plc
  • Merz Pharma GmbH & Co. KGaA
  • Novartis AG
  • Pfizer Inc.
  • Piramal Enterprises Ltd.
  • Revance Therapeutics, Inc.
  • RVL Pharmaceuticals Ltd.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UCB Pharma S.A.

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 큐레이트된 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.08.28

Global Spasticity Treatment Market to Reach US$7.2 Billion by 2030

The global market for Spasticity Treatment estimated at US$5.9 Billion in the year 2024, is expected to reach US$7.2 Billion by 2030, growing at a CAGR of 3.2% over the analysis period 2024-2030. Spasticity Drug Therapy, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$4.6 Billion by the end of the analysis period. Growth in the Spasticity Physical Therapy segment is estimated at 1.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.6 Billion While China is Forecast to Grow at 6.2% CAGR

The Spasticity Treatment market in the U.S. is estimated at US$1.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 6.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.

Global Spasticity Treatment Market - Key Trends & Drivers Summarized

Managing Muscle Tone Disorders: How Emerging Therapies Are Redefining Spasticity Care and Patient Outcomes

What Is Spasticity and Why Is It Becoming an Increasingly Prioritized Neurological Treatment Area?

Spasticity is a neuromuscular condition characterized by involuntary muscle stiffness, exaggerated reflexes, and resistance to passive movement, often resulting from central nervous system damage. Common underlying causes include multiple sclerosis (MS), cerebral palsy (CP), traumatic brain injury (TBI), stroke, and spinal cord injury. Spasticity not only impairs mobility and dexterity but also contributes to joint contractures, pain, and long-term disability, significantly affecting patient quality of life and caregiver burden.

As diagnostic capabilities and post-acute care systems improve globally, there is greater awareness and detection of spasticity-related complications. The condition is increasingly seen not just as a symptom but as a modifiable therapeutic target with broad quality-of-life implications. Clinical management now includes multidisciplinary interventions spanning pharmacologic, rehabilitative, surgical, and neuromodulatory approaches. The growing demand for patient-centric, function-restoring solutions is expanding the scope of spasticity treatment across both pediatric and adult populations.

What Are the Leading Therapeutic Approaches and Which Innovations Are Transforming Patient Management?

Pharmacological therapy remains the first line of treatment, with oral antispasmodics such as baclofen, tizanidine, diazepam, and dantrolene being commonly prescribed. However, these agents often produce systemic side effects like sedation, hypotension, or hepatotoxicity, limiting long-term use. As a result, focal therapies such as botulinum toxin type A (BoNT-A) injections have gained traction. These neuromuscular blocking agents selectively inhibit acetylcholine release at the neuromuscular junction, offering targeted relief with fewer systemic effects. Brands like Botox (Allergan), Dysport (Ipsen), and Xeomin (Merz) dominate this segment, supported by extensive clinical trial data across upper and lower limb spasticity.

Intrathecal baclofen therapy (ITB) is another advanced intervention for severe generalized spasticity. This involves implanting a programmable pump to deliver baclofen directly to the spinal cord, reducing systemic exposure and improving efficacy. ITB is particularly beneficial for patients with cerebral palsy, spinal cord injury, or severe post-stroke spasticity. Surgical options, including tendon release and selective dorsal rhizotomy, are reserved for refractory cases or when deformity correction is needed. Physical and occupational therapy remain essential adjuncts, focusing on muscle stretching, splinting, and functional retraining.

Emerging innovations include neuromodulation techniques such as transcranial magnetic stimulation (TMS) and electrical stimulation therapies, which aim to modulate spinal reflex circuits and improve voluntary motor control. Digital therapeutics, AI-enabled gait analysis, and wearable electromyography (EMG) sensors are also being integrated into spasticity management pathways, providing objective monitoring and tailored therapy adjustments. Stem cell research and regenerative therapies are in early exploratory phases for neuroplasticity enhancement, especially in spinal cord and cerebral injury cases.

Which Regions Are Driving Growth in Spasticity Care and How Are Delivery Models Evolving?

North America leads the global spasticity treatment market due to high disease awareness, widespread access to advanced therapeutics, and a strong ecosystem of neurology and rehabilitation centers. The U.S. is a key market for BoNT-A treatments, with extensive insurance coverage and patient advocacy groups supporting early diagnosis and intervention. Government-funded programs such as Medicaid and Veterans Affairs also cover surgical and device-based treatments, expanding access to underserved populations.

Europe follows closely, with strong adoption of botulinum toxin therapy across countries like Germany, France, the UK, and the Nordics. National health services provide reimbursement for pharmacologic and surgical treatments, while research institutions are active in evaluating newer techniques such as combined pharmacologic and robotic therapy. Rehabilitation networks and stroke units in the region emphasize integrated spasticity management, often using multidisciplinary teams that include physiatrists, neurologists, orthopedic surgeons, and therapists.

Asia-Pacific is an emerging hotspot, driven by increasing stroke and trauma incidence, improved rehabilitation access, and rising healthcare investments in countries such as China, Japan, India, and South Korea. Although awareness and specialist availability remain uneven, urban centers are witnessing rapid growth in demand for BoNT-A and ITB therapies. Latin America and the Middle East are gradually expanding spasticity services, supported by medical tourism, telehealth consultations, and public-private partnerships focused on disability care.

What Is Fueling Market Growth and Where Are Future Treatment Frontiers Expected to Emerge?

The growth in the global spasticity treatment market is driven by several factors including rising prevalence of neurovascular and neurodegenerative disorders, improved post-injury survival rates, and the emergence of minimally invasive, personalized therapy options. As healthcare systems prioritize long-term functional outcomes and disability reduction, spasticity management is being integrated into broader neurorehabilitation frameworks. The increasing adoption of injectable biologics and programmable drug delivery systems reflects a shift toward targeted, sustainable treatment paradigms.

Pipeline opportunities include next-generation botulinum toxin formulations with longer duration of effect, improved safety profiles, and faster onset. Companies are developing biosimilars and expanded indication sets for pediatric and post-trauma populations. Combination therapies-such as BoNT-A with robotics or functional electrical stimulation-are showing promise in improving motor function and reducing caregiver dependence. Additionally, AI-enabled rehabilitation platforms that adapt therapy intensity based on user data are gaining interest among providers and payers.

As the definition of therapeutic success evolves beyond muscle tone reduction to include quality-of-life metrics, functional independence, and patient-reported outcomes, the spasticity treatment market is set to expand into a holistic, tech-enabled domain. Strategic investments in integrated care models, neurotechnology, and digital biomarker tracking will play a pivotal role in shaping the future of spasticity care worldwide.

SCOPE OF STUDY:

The report analyzes the Spasticity Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Spasticity Drug Therapy, Spasticity Physical Therapy, Surgical Treatment for Spasticity); Administration Route (Oral Administration, Parenteral Administration); Indication (Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication, Other Indications); End-Use (Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use, Diagnostic Centers End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • AbbVie Inc. (Allergan)
  • Acorda Therapeutics, Inc.
  • Amneal Pharmaceuticals, Inc.
  • Assertio Therapeutics, Inc.
  • Beximco Pharmaceuticals Ltd.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc (GSK)
  • InMed Pharmaceuticals Inc.
  • Ipsen Biopharmaceuticals, Inc.
  • Jazz Pharmaceuticals plc
  • Merz Pharma GmbH & Co. KGaA
  • Novartis AG
  • Pfizer Inc.
  • Piramal Enterprises Ltd.
  • Revance Therapeutics, Inc.
  • RVL Pharmaceuticals Ltd.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UCB Pharma S.A.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Spasticity Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Neurological Disorders Drives Demand for Spasticity Management Therapies
    • Increased Awareness of Stroke Rehabilitation Enhances Early Diagnosis and Intervention Rates
    • Growing Use of Botulinum Toxin Injections Supports Non-Surgical Treatment Pathways
    • Development of Targeted Drug Delivery Mechanisms Improves Efficacy of Pharmacological Interventions
    • Surge in Clinical Trials Evaluating Novel Antispastic Agents Expands Therapeutic Pipeline
    • Integration of Physical Therapy With Pharmacologic Protocols Promotes Multimodal Care Models
    • Increased Availability of Intrathecal Baclofen Pumps Boosts Patient-Specific Treatment Adoption
    • Progress in Neurorehabilitation Robotics and Exoskeletons Supports Functional Recovery
    • Rising Demand for Home-Based Rehabilitation Technologies Enhances Patient Engagement
    • Expansion of Pediatric Spasticity Treatment Programs Broadens Access to Early Interventions
    • Use of Digital Health and Mobile Apps Supports Monitoring of Spasticity Severity and Outcomes
    • Government Support for Disability Management Enhances Reimbursement and Insurance Access
    • Collaboration Between Neurologists, Orthopedists, and Rehab Specialists Optimizes Treatment Outcomes
    • Adoption of Customized Orthotic Devices Improves Mobility in Spasticity Patients
    • Increased Focus on Post-Surgical Spasticity Management Drives Innovation in Adjunct Therapies
    • Emergence of Gene Therapy Research for Spasticity Signals Long-Term Potential
    • Rising Prevalence of Cerebral Palsy and Multiple Sclerosis Fuels Chronic Care Requirements
    • Advancement in MRI and EMG-Guided Interventions Supports Precision Targeting
    • Educational Campaigns and Advocacy Support Early Referral and Diagnosis
    • Growing Interest in Cannabinoid-Based Spasticity Medications Drives Regulatory Submissions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Spasticity Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Spasticity Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Spasticity Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Spasticity Drug Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Spasticity Drug Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Spasticity Physical Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Spasticity Physical Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Surgical Treatment for Spasticity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Surgical Treatment for Spasticity by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Home Care Settings End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Home Care Settings End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Specialty Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Diagnostic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Diagnostic Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Parenteral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Parenteral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Cerebral Palsy Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Cerebral Palsy Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Multiple Sclerosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Multiple Sclerosis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Traumatic Brain Injury Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for Traumatic Brain Injury Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 30: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 31: World 6-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Spasticity Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
    • TABLE 34: USA Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: USA 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
    • TABLE 36: USA Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: USA 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
  • CANADA
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Canada 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
    • TABLE 42: Canada Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Canada 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
    • TABLE 46: Canada Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Canada 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
  • JAPAN
    • Spasticity Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 48: Japan Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Japan 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
    • TABLE 52: Japan Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Japan 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
    • TABLE 54: Japan Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Japan 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
  • CHINA
    • Spasticity Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
    • TABLE 58: China Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: China 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
    • TABLE 60: China Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: China 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
  • EUROPE
    • Spasticity Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 64: Europe Recent Past, Current & Future Analysis for Spasticity Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 65: Europe 6-Year Perspective for Spasticity Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 66: Europe Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Europe 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
    • TABLE 70: Europe Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Europe 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
    • TABLE 72: Europe Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Europe 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
  • FRANCE
    • Spasticity Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
    • TABLE 76: France Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: France 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
    • TABLE 78: France Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: France 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
  • GERMANY
    • Spasticity Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 82: Germany Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Germany 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
    • TABLE 84: Germany Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Germany 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
    • TABLE 88: Germany Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Germany 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
  • ITALY
    • TABLE 90: Italy Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Italy 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Italy 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
    • TABLE 94: Italy Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Italy 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
    • TABLE 96: Italy Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Italy 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
  • UNITED KINGDOM
    • Spasticity Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 98: UK Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: UK 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
    • TABLE 100: UK Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: UK 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
    • TABLE 102: UK Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: UK 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
  • SPAIN
    • TABLE 106: Spain Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Spain 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
    • TABLE 108: Spain Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Spain 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
    • TABLE 110: Spain Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Spain 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
    • TABLE 112: Spain Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Spain 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
  • RUSSIA
    • TABLE 114: Russia Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 115: Russia 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
    • TABLE 116: Russia Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Russia 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
    • TABLE 118: Russia Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Russia 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
    • TABLE 120: Russia Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Russia 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Europe 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
    • TABLE 124: Rest of Europe Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Rest of Europe 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
    • TABLE 126: Rest of Europe Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 127: Rest of Europe 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
    • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Europe 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Spasticity Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 130: Asia-Pacific Recent Past, Current & Future Analysis for Spasticity Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 131: Asia-Pacific 6-Year Perspective for Spasticity Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2025 & 2030
    • TABLE 132: Asia-Pacific Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 133: Asia-Pacific 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
    • TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Asia-Pacific 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
    • TABLE 136: Asia-Pacific Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 137: Asia-Pacific 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
    • TABLE 138: Asia-Pacific Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 139: Asia-Pacific 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
  • AUSTRALIA
    • Spasticity Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 140: Australia Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Australia 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
    • TABLE 142: Australia Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 143: Australia 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
    • TABLE 144: Australia Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 145: Australia 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
    • TABLE 146: Australia Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Australia 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
  • INDIA
    • Spasticity Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 148: India Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 149: India 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
    • TABLE 150: India Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 151: India 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
    • TABLE 152: India Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: India 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
    • TABLE 154: India Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 155: India 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
  • SOUTH KOREA
    • TABLE 156: South Korea Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 157: South Korea 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
    • TABLE 158: South Korea Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: South Korea 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
    • TABLE 160: South Korea Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 161: South Korea 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
    • TABLE 162: South Korea Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 163: South Korea 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 164: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Asia-Pacific 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
    • TABLE 166: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 167: Rest of Asia-Pacific 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
    • TABLE 168: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 169: Rest of Asia-Pacific 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
    • TABLE 170: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Asia-Pacific 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
  • LATIN AMERICA
    • Spasticity Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 172: Latin America Recent Past, Current & Future Analysis for Spasticity Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 173: Latin America 6-Year Perspective for Spasticity Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2025 & 2030
    • TABLE 174: Latin America Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 175: Latin America 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
    • TABLE 176: Latin America Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Latin America 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
    • TABLE 178: Latin America Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 179: Latin America 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
    • TABLE 180: Latin America Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 181: Latin America 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
  • ARGENTINA
    • TABLE 182: Argentina Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Argentina 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
    • TABLE 184: Argentina Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 185: Argentina 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
    • TABLE 186: Argentina Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 187: Argentina 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
    • TABLE 188: Argentina Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Argentina 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
  • BRAZIL
    • TABLE 190: Brazil Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 191: Brazil 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
    • TABLE 192: Brazil Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 193: Brazil 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
    • TABLE 194: Brazil Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Brazil 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
    • TABLE 196: Brazil Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 197: Brazil 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
  • MEXICO
    • TABLE 198: Mexico Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 199: Mexico 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
    • TABLE 200: Mexico Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Mexico 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
    • TABLE 202: Mexico Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 203: Mexico 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
    • TABLE 204: Mexico Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 205: Mexico 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 206: Rest of Latin America Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Latin America 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
    • TABLE 208: Rest of Latin America Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 209: Rest of Latin America 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
    • TABLE 210: Rest of Latin America Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 211: Rest of Latin America 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
    • TABLE 212: Rest of Latin America Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Rest of Latin America 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
  • MIDDLE EAST
    • Spasticity Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 214: Middle East Recent Past, Current & Future Analysis for Spasticity Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 215: Middle East 6-Year Perspective for Spasticity Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2025 & 2030
    • TABLE 216: Middle East Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 217: Middle East 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
    • TABLE 218: Middle East Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Middle East 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
    • TABLE 220: Middle East Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 221: Middle East 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
    • TABLE 222: Middle East Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 223: Middle East 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
  • IRAN
    • TABLE 224: Iran Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Iran 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
    • TABLE 226: Iran Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 227: Iran 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
    • TABLE 228: Iran Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 229: Iran 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
    • TABLE 230: Iran Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Iran 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
  • ISRAEL
    • TABLE 232: Israel Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 233: Israel 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
    • TABLE 234: Israel Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 235: Israel 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
    • TABLE 236: Israel Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Israel 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
    • TABLE 238: Israel Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 239: Israel 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
  • SAUDI ARABIA
    • TABLE 240: Saudi Arabia Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 241: Saudi Arabia 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
    • TABLE 242: Saudi Arabia Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Saudi Arabia 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
    • TABLE 244: Saudi Arabia Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 245: Saudi Arabia 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
    • TABLE 246: Saudi Arabia Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 247: Saudi Arabia 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 248: UAE Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: UAE 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
    • TABLE 250: UAE Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 251: UAE 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
    • TABLE 252: UAE Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 253: UAE 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
    • TABLE 254: UAE Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: UAE 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 256: Rest of Middle East Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 257: Rest of Middle East 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
    • TABLE 258: Rest of Middle East Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 259: Rest of Middle East 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
    • TABLE 260: Rest of Middle East Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Rest of Middle East 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
    • TABLE 262: Rest of Middle East Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 263: Rest of Middle East 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030
  • AFRICA
    • Spasticity Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 264: Africa Recent Past, Current & Future Analysis for Spasticity Treatment by Type - Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 265: Africa 6-Year Perspective for Spasticity Treatment by Type - Percentage Breakdown of Value Sales for Spasticity Drug Therapy, Spasticity Physical Therapy and Surgical Treatment for Spasticity for the Years 2025 & 2030
    • TABLE 266: Africa Recent Past, Current & Future Analysis for Spasticity Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Africa 6-Year Perspective for Spasticity Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Home Care Settings End-Use, Specialty Clinics End-Use and Diagnostic Centers End-Use for the Years 2025 & 2030
    • TABLE 268: Africa Recent Past, Current & Future Analysis for Spasticity Treatment by Administration Route - Oral Administration and Parenteral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 269: Africa 6-Year Perspective for Spasticity Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration and Parenteral Administration for the Years 2025 & 2030
    • TABLE 270: Africa Recent Past, Current & Future Analysis for Spasticity Treatment by Indication - Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 271: Africa 6-Year Perspective for Spasticity Treatment by Indication - Percentage Breakdown of Value Sales for Cerebral Palsy Indication, Multiple Sclerosis Indication, Traumatic Brain Injury Indication and Other Indications for the Years 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제